Muscle mass and physical function in patients with bladder cancer-Data from a prematurely terminated prospective cohort study.
anticancer treatment adherence
bladder cancer
frailty
physical performance
sarcopenia
Journal
Frontiers in rehabilitation sciences
ISSN: 2673-6861
Titre abrégé: Front Rehabil Sci
Pays: Switzerland
ID NLM: 9918227358906676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
05
2022
accepted:
20
09
2022
entrez:
24
10
2022
pubmed:
25
10
2022
medline:
25
10
2022
Statut:
epublish
Résumé
Patients with bladder cancer (BC) have a high prevalence of comorbidity and low adherence to systemic anticancer treatment but it is unknown whether this is associated with sarcopenia. We aimed to investigate if the sarcopenia-defining parameters (muscle strength, muscle mass and physical performance) were associated with reduced adherence to systemic anticancer treatment in patients with BC, and if these muscle domains changed during treatment. Patients >18 years of age with BC referred for chemotherapy or immunotherapy at Department of Oncology, Rigshospitalet, Denmark were eligible for study inclusion. Measurements were performed before treatment initiation and within one week after treatment termination, and consisted of assessments of muscle strength, muscle mass, and physical performance. Data was compared with thresholds outlined by the European Working Group on Sarcopenia in Older Patient's (EWGSOP2) guidelines and a healthy, age-matched Danish cohort. Over a period of 29 months, we included 14 patients of whom two completed follow-up measurements. The recruitment rate was <50% of planned due to logistics and Covid-19 related limitations. Consequently, a decision to prematurely terminate the study was made. No patients fulfilled EWGSOP2 criteria for sarcopenia, but the majority had reduction in one or more muscle domains compared to healthy, age-matched individuals. The majority of patients had poor treatment tolerance, leading to dose reductions and postponed treatments. In this prematurely terminated study, no patients fulfilled EWGSOP2 criteria for sarcopenia, yet, most patients were affected in one or more muscle domains and the majority had compromised treatment adherence.
Sections du résumé
Background
UNASSIGNED
Patients with bladder cancer (BC) have a high prevalence of comorbidity and low adherence to systemic anticancer treatment but it is unknown whether this is associated with sarcopenia.
Objective
UNASSIGNED
We aimed to investigate if the sarcopenia-defining parameters (muscle strength, muscle mass and physical performance) were associated with reduced adherence to systemic anticancer treatment in patients with BC, and if these muscle domains changed during treatment.
Methods
UNASSIGNED
Patients >18 years of age with BC referred for chemotherapy or immunotherapy at Department of Oncology, Rigshospitalet, Denmark were eligible for study inclusion. Measurements were performed before treatment initiation and within one week after treatment termination, and consisted of assessments of muscle strength, muscle mass, and physical performance. Data was compared with thresholds outlined by the European Working Group on Sarcopenia in Older Patient's (EWGSOP2) guidelines and a healthy, age-matched Danish cohort.
Results
UNASSIGNED
Over a period of 29 months, we included 14 patients of whom two completed follow-up measurements. The recruitment rate was <50% of planned due to logistics and Covid-19 related limitations. Consequently, a decision to prematurely terminate the study was made. No patients fulfilled EWGSOP2 criteria for sarcopenia, but the majority had reduction in one or more muscle domains compared to healthy, age-matched individuals. The majority of patients had poor treatment tolerance, leading to dose reductions and postponed treatments.
Conclusions
UNASSIGNED
In this prematurely terminated study, no patients fulfilled EWGSOP2 criteria for sarcopenia, yet, most patients were affected in one or more muscle domains and the majority had compromised treatment adherence.
Identifiants
pubmed: 36275921
doi: 10.3389/fresc.2022.942475
pmc: PMC9582947
doi:
Types de publication
Journal Article
Langues
eng
Pagination
942475Informations de copyright
© 2022 Omland, Ammitzbøll, Lund, Lindberg, Dalton, Suetta and Pappot.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Haematol. 2020 Jun;7(6):e432-e435
pubmed: 32339482
Clin Nutr. 2016 Dec;35(6):1386-1393
pubmed: 27102408
Eur J Cancer. 2020 Dec;141:82-91
pubmed: 33129040
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Health Qual Life Outcomes. 2020 Jul 11;18(1):225
pubmed: 32653005
Eur Urol. 2014 Apr;65(4):778-92
pubmed: 24373477
Knee Surg Sports Traumatol Arthrosc. 2020 Oct;28(10):3087-3093
pubmed: 32926255
Ann Oncol. 2014 May;25(5):947-58
pubmed: 24401927
Clin Interv Aging. 2015 Jun 10;10:939-49
pubmed: 26089655
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1316-1329
pubmed: 31419087
J Am Geriatr Soc. 2010 Jan;58(1):76-82
pubmed: 20122042
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
Oncologist. 2021 Dec;26(12):1017-1025
pubmed: 34342095
Semin Oncol Nurs. 2021 Feb;37(1):151108
pubmed: 33431235
Front Med (Lausanne). 2020 Dec 23;7:598038
pubmed: 33425945
Clin Cancer Res. 2020 Jul 1;26(13):3100-3103
pubmed: 32312892
Clin Nutr. 2021 May;40(5):2809-2816
pubmed: 33933747
Eur Urol Open Sci. 2020 Oct;21:22-28
pubmed: 33123688
Eur J Surg Oncol. 2015 Mar;41(3):333-8
pubmed: 25498359